Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey

Anuradha Kanaparthi,1 Sarah Kukura,2 Natalie Slenkovich,2 Faris AlGhamdi,2 Shabana Z Shafy,2 Mohammed Hakim,2 Joseph D Tobias2,3 1College of Medicine, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio, USA; 2Department of Anesthesiology & Pain Medicine, Nationwide Children&rsqu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kanaparthi A, Kukura S, Slenkovich N, AlGhamdi F, Shafy SZ, Hakim M, Tobias JD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	aprepitant postoperative nausea and vomiting pediatric Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/cd955e2ce1254cfb9ef0ceadcf1829fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd955e2ce1254cfb9ef0ceadcf1829fd
record_format	dspace
spelling	oai:doaj.org-article:cd955e2ce1254cfb9ef0ceadcf1829fd2021-12-02T09:15:39ZPerioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey1179-1438https://doaj.org/article/cd955e2ce1254cfb9ef0ceadcf1829fd2019-11-01T00:00:00Zhttps://www.dovepress.com/perioperative-administration-of-emendreg-aprepitant-at-a-tertiary-care-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Anuradha Kanaparthi,1 Sarah Kukura,2 Natalie Slenkovich,2 Faris AlGhamdi,2 Shabana Z Shafy,2 Mohammed Hakim,2 Joseph D Tobias2,3 1College of Medicine, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio, USA; 2Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, Ohio, USA; 3Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USACorrespondence: Anuradha KanaparthiDepartment of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, Ohio 43205 Tel +1614 722-4200Fax +1614 722-4203Email akanaparthi@neomed.eduIntroduction: Aprepitant (Emend®) is a novel antiemetic agent that works through antagonism of neurokinin-1 (NK-1) receptors. To date, there are limited data regarding its use to prevent postoperative nausea and vomiting (PONV) in children. We retrospectively reviewed our initial 12-months experience with aprepitant after it was made available for perioperative use.Methods: The anesthetic records of patients who received aprepitant were retrospectively reviewed and demographic, surgical, and medication data retrieved.Results: The study cohort included 31 patients (15 male and 16 female) ranging in age from 4 to 27 years (15.7 ± 7.4 years) and in weight from 14.4 to 175.7 kilograms (59.3 ± 30.2 kgs). Most of the patients (30 of 31) received the capsule form and 1 received the liquid. The average dose of aprepitant administered was 0.9 ± 0.6 mg/kg; however, only one patient received dosing expressed as mg/kg, and the majority received a 40 mg capsule. All of the patients in the cohort had either a previous history of PONV or risk factors for PONV. PONV occurred in the PACU in 1 patient and during the first 24 postoperative hours in 3 additional patients. No adverse effects related to aprepitant use were noted.Conclusion: Aprepitant was easily added to the preoperative regimen for pediatric patients who may require it. Our approach limited overuse and subsequent cost concerns. Future studies with a comparator group and a greater sample size are needed to demonstrate its efficacy, especially in comparison to time-honored agents such as ondansetron. No adverse effects were noted in our limited study cohort.Keywords: aprepitant, postoperative nausea and vomiting, pediatricKanaparthi AKukura SSlenkovich NAlGhamdi FShafy SZHakim MTobias JDDove Medical Pressarticleaprepitantpostoperative nausea and vomitingpediatricTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 11, Pp 155-160 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	aprepitant postoperative nausea and vomiting pediatric Therapeutics. Pharmacology RM1-950
spellingShingle	aprepitant postoperative nausea and vomiting pediatric Therapeutics. Pharmacology RM1-950 Kanaparthi A Kukura S Slenkovich N AlGhamdi F Shafy SZ Hakim M Tobias JD Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
description	Anuradha Kanaparthi,1 Sarah Kukura,2 Natalie Slenkovich,2 Faris AlGhamdi,2 Shabana Z Shafy,2 Mohammed Hakim,2 Joseph D Tobias2,3 1College of Medicine, Northeast Ohio Medical University (NEOMED), Rootstown, Ohio, USA; 2Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, Ohio, USA; 3Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USACorrespondence: Anuradha KanaparthiDepartment of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, Ohio 43205 Tel +1614 722-4200Fax +1614 722-4203Email akanaparthi@neomed.eduIntroduction: Aprepitant (Emend®) is a novel antiemetic agent that works through antagonism of neurokinin-1 (NK-1) receptors. To date, there are limited data regarding its use to prevent postoperative nausea and vomiting (PONV) in children. We retrospectively reviewed our initial 12-months experience with aprepitant after it was made available for perioperative use.Methods: The anesthetic records of patients who received aprepitant were retrospectively reviewed and demographic, surgical, and medication data retrieved.Results: The study cohort included 31 patients (15 male and 16 female) ranging in age from 4 to 27 years (15.7 ± 7.4 years) and in weight from 14.4 to 175.7 kilograms (59.3 ± 30.2 kgs). Most of the patients (30 of 31) received the capsule form and 1 received the liquid. The average dose of aprepitant administered was 0.9 ± 0.6 mg/kg; however, only one patient received dosing expressed as mg/kg, and the majority received a 40 mg capsule. All of the patients in the cohort had either a previous history of PONV or risk factors for PONV. PONV occurred in the PACU in 1 patient and during the first 24 postoperative hours in 3 additional patients. No adverse effects related to aprepitant use were noted.Conclusion: Aprepitant was easily added to the preoperative regimen for pediatric patients who may require it. Our approach limited overuse and subsequent cost concerns. Future studies with a comparator group and a greater sample size are needed to demonstrate its efficacy, especially in comparison to time-honored agents such as ondansetron. No adverse effects were noted in our limited study cohort.Keywords: aprepitant, postoperative nausea and vomiting, pediatric
format	article
author	Kanaparthi A Kukura S Slenkovich N AlGhamdi F Shafy SZ Hakim M Tobias JD
author_facet	Kanaparthi A Kukura S Slenkovich N AlGhamdi F Shafy SZ Hakim M Tobias JD
author_sort	Kanaparthi A
title	Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
title_short	Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
title_full	Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
title_fullStr	Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
title_full_unstemmed	Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey
title_sort	perioperative administration of emend® (aprepitant) at a tertiary care children’s hospital: a 12-month survey
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/cd955e2ce1254cfb9ef0ceadcf1829fd
work_keys_str_mv	AT kanaparthia perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT kukuras perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT slenkovichn perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT alghamdif perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT shafysz perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT hakimm perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey AT tobiasjd perioperativeadministrationofemendaprepitantatatertiarycarechildrenshospitala12monthsurvey
_version_	1718398212443734016

Perioperative Administration of Emend® (Aprepitant) at a Tertiary Care Children’s Hospital: A 12-Month Survey

Ejemplares similares